Skip to main content
Top
Published in: Rheumatology International 12/2012

01-12-2012 | Original Article

25-Hydroxyvitamin D levels and juvenile idiopathic arthritis: Is there an association with disease activity?

Authors: Christina F. Pelajo, Jorge M. Lopez-Benitez, David M. Kent, Lori Lyn Price, Laurie C. Miller, Bess Dawson-Hughes

Published in: Rheumatology International | Issue 12/2012

Login to get access

Abstract

The aims of this study were to examine the association between serum levels of 25-hydroxyvitamin D [25(OH)D] and disease activity in juvenile idiopathic arthritis (JIA), to determine the prevalence of vitamin D (VD) deficiency [25(OH)D ≤19 ng/ml] and insufficiency [25(OH)D 20–29 ng/ml], and to determine factors associated with lower serum levels of 25(OH)D in this population. In this cross-sectional study, disease activity was measured using JADAS-27, as well as its individual components (physician global assessment of disease activity, parent global assessment of child’s well-being, count of joints with active disease, and erythrocyte sedimentation rate). Linear regression models were developed to analyze the association between serum 25(OH)D levels and JADAS-27 and to determine variables associated with serum 25(OH)D levels. A total of 154 patients (61% girls, 88% whites) were included. Mean age was 10.6. VD deficiency was detected in 13% and insufficiency in 42%. In univariate and multivariate analyses, 25(OH)D levels were not associated with JADAS-27, neither with its individual components. However, in a subset analysis including all new-onset JIA patients (n = 27), there was a nonsignificant negative correlation between serum 25(OH)D levels and JADAS-27 (r = −0.29, P = 0.14). In the univariate and multivariate analyses, age, ethnicity, BMI, and season were significantly associated with serum 25(OH)D levels, but not total VD intake. More than 1/2 of JIA patients had serum 25(OH)D levels below 29 ng/ml; however, there was no association between serum 25(OH)D levels and disease activity. Future larger, long-term studies with new-onset JIA patients are needed to further explore the association between serum 25(OH)D levels and disease activity.
Literature
3.
go back to reference Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179(3):1634–1647. doi:179/3/1634 PubMed Chen S, Sims GP, Chen XX, Gu YY, Lipsky PE (2007) Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179(3):1634–1647. doi:179/​3/​1634 PubMed
4.
5.
go back to reference Lemire J (2000) 1, 25-Dihydroxyvitamin D3—a hormone with immunomodulatory properties. Z Rheumatol 59(Suppl 1):24–27PubMedCrossRef Lemire J (2000) 1, 25-Dihydroxyvitamin D3—a hormone with immunomodulatory properties. Z Rheumatol 59(Suppl 1):24–27PubMedCrossRef
6.
go back to reference Lemire JM, Archer DC, Beck L, Spiegelberg HL (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125(6 Suppl):1704S–1708SPubMed Lemire JM, Archer DC, Beck L, Spiegelberg HL (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125(6 Suppl):1704S–1708SPubMed
8.
go back to reference van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1 alpha, 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23(3):233–239. doi:10.1016/j.jaut.2004.06.004 PubMedCrossRef van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO (2004) 1 alpha, 25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23(3):233–239. doi:10.​1016/​j.​jaut.​2004.​06.​004 PubMedCrossRef
13.
go back to reference Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14(4):397–400PubMedCrossRef Muller K, Kriegbaum NJ, Baslund B, Sorensen OH, Thymann M, Bentzen K (1995) Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol 14(4):397–400PubMedCrossRef
14.
go back to reference Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47(6):920–923. doi:10.1093/rheumatology/ken121 CrossRef Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47(6):920–923. doi:10.​1093/​rheumatology/​ken121 CrossRef
17.
go back to reference Becker A, Fischer R, Schneider M (2001) Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z Rheumatol 60(5):352–358PubMedCrossRef Becker A, Fischer R, Schneider M (2001) Bone density and 25-OH vitamin D serum level in patients with systemic lupus erythematosus. Z Rheumatol 60(5):352–358PubMedCrossRef
19.
go back to reference Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG (2004) Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 50(1):72–77. doi:10.1002/art.11434 PubMedCrossRef Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG (2004) Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 50(1):72–77. doi:10.​1002/​art.​11434 PubMedCrossRef
20.
21.
go back to reference Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D (2007) Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 56(7):2143–2149. doi:10.1002/art.22722 PubMedCrossRef Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D (2007) Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 56(7):2143–2149. doi:10.​1002/​art.​22722 PubMedCrossRef
22.
go back to reference Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B (2006) Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 24(6):702–704. doi:1964 PubMed Cutolo M, Otsa K, Laas K, Yprus M, Lehtme R, Secchi ME, Sulli A, Paolino S, Seriolo B (2006) Circannual vitamin d serum levels and disease activity in rheumatoid arthritis: Northern versus Southern Europe. Clin Exp Rheumatol 24(6):702–704. doi:1964 PubMed
23.
go back to reference Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62(3):193–198PubMedCrossRef Oelzner P, Muller A, Deschner F, Huller M, Abendroth K, Hein G, Stein G (1998) Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 62(3):193–198PubMedCrossRef
24.
go back to reference Lange U, Teichmann J, Strunk J, Muller-Ladner U, Schmidt KL (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16(12):1999–2004. doi:10.1007/s00198-005-1990-5 PubMedCrossRef Lange U, Teichmann J, Strunk J, Muller-Ladner U, Schmidt KL (2005) Association of 1.25 vitamin D3 deficiency, disease activity and low bone mass in ankylosing spondylitis. Osteoporos Int 16(12):1999–2004. doi:10.​1007/​s00198-005-1990-5 PubMedCrossRef
27.
go back to reference Bianchi ML, Bardare M, Caraceni MP, Cohen E, Falvella S, Borzani M, DeGaspari MG (1990) Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 9(2):153–162PubMedCrossRef Bianchi ML, Bardare M, Caraceni MP, Cohen E, Falvella S, Borzani M, DeGaspari MG (1990) Bone metabolism in juvenile rheumatoid arthritis. Bone Miner 9(2):153–162PubMedCrossRef
28.
go back to reference Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658–666. doi:10.1002/art.24516 PubMedCrossRef Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A (2009) Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 61(5):658–666. doi:10.​1002/​art.​24516 PubMedCrossRef
32.
go back to reference Update (1997) Prevalence of overweight among children, adolescents, and adults–United States, 1988–1994. MMWR Morb Mortal Wkly Rep 46(9):198–202 Update (1997) Prevalence of overweight among children, adolescents, and adults–United States, 1988–1994. MMWR Morb Mortal Wkly Rep 46(9):198–202
33.
go back to reference Harris SS, Dawson-Hughes B (1998) The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr 17(3):282–284PubMed Harris SS, Dawson-Hughes B (1998) The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr 17(3):282–284PubMed
35.
go back to reference Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(6 Suppl):1678S–1688S. doi:80/6/1678S PubMed Holick MF (2004) Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 80(6 Suppl):1678S–1688S. doi:80/​6/​1678S PubMed
40.
go back to reference Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R (2008) Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 93(9):3430–3435. doi:10.1210/jc.2008-0241 PubMedCrossRef Ish-Shalom S, Segal E, Salganik T, Raz B, Bromberg IL, Vieth R (2008) Comparison of daily, weekly, and monthly vitamin D3 in ethanol dosing protocols for two months in elderly hip fracture patients. J Clin Endocrinol Metab 93(9):3430–3435. doi:10.​1210/​jc.​2008-0241 PubMedCrossRef
41.
go back to reference Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, Silverman ED (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984. doi:10.1002/art.22709 PubMedCrossRef Saurenmann RK, Rose JB, Tyrrell P, Feldman BM, Laxer RM, Schneider R, Silverman ED (2007) Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 56(6):1974–1984. doi:10.​1002/​art.​22709 PubMedCrossRef
42.
go back to reference Schwartz MM, Simpson P, Kerr KL, Jarvis JN (1997) Juvenile rheumatoid arthritis in African Americans. J Rheumatol 24(9):1826–1829PubMed Schwartz MM, Simpson P, Kerr KL, Jarvis JN (1997) Juvenile rheumatoid arthritis in African Americans. J Rheumatol 24(9):1826–1829PubMed
44.
go back to reference Dong Y, Pollock N, Stallmann-Jorgensen IS, Gutin B, Lan L, Chen TC, Keeton D, Petty K, Holick MF, Zhu H (2010) Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. Pediatrics 125(6):1104–1111. doi:10.1542/peds.2009-2055 PubMedCrossRef Dong Y, Pollock N, Stallmann-Jorgensen IS, Gutin B, Lan L, Chen TC, Keeton D, Petty K, Holick MF, Zhu H (2010) Low 25-hydroxyvitamin D levels in adolescents: race, season, adiposity, physical activity, and fitness. Pediatrics 125(6):1104–1111. doi:10.​1542/​peds.​2009-2055 PubMedCrossRef
Metadata
Title
25-Hydroxyvitamin D levels and juvenile idiopathic arthritis: Is there an association with disease activity?
Authors
Christina F. Pelajo
Jorge M. Lopez-Benitez
David M. Kent
Lori Lyn Price
Laurie C. Miller
Bess Dawson-Hughes
Publication date
01-12-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 12/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2287-y

Other articles of this Issue 12/2012

Rheumatology International 12/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine